258 related articles for article (PubMed ID: 28903332)
1. Myeloid-derived suppressor cell and macrophage exert distinct angiogenic and immunosuppressive effects in breast cancer.
Fang Z; Wen C; Chen X; Yin R; Zhang C; Wang X; Huang Y
Oncotarget; 2017 Aug; 8(33):54173-54186. PubMed ID: 28903332
[TBL] [Abstract][Full Text] [Related]
2. Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.
Fujimura T; Aiba S
Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32707850
[TBL] [Abstract][Full Text] [Related]
3. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
[TBL] [Abstract][Full Text] [Related]
4. Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.
Cresswell GM; Wang B; Kischuk EM; Broman MM; Alfar RA; Vickman RE; Dimitrov DS; Kularatne SA; Sundaram CP; Singhal S; Eruslanov EB; Crist SA; Elzey BD; Ratliff TL; Low PS
Cancer Res; 2021 Feb; 81(3):671-684. PubMed ID: 33203700
[TBL] [Abstract][Full Text] [Related]
5. Myeloid suppressor cells in cancer and autoimmunity.
Sica A; Massarotti M
J Autoimmun; 2017 Dec; 85():117-125. PubMed ID: 28728794
[TBL] [Abstract][Full Text] [Related]
6. Novel adherent CD11b
Tsubaki T; Kadonosono T; Sakurai S; Shiozawa T; Goto T; Sakai S; Kuchimaru T; Sakamoto T; Watanabe H; Kondoh G; Kizaka-Kondoh S
Oncotarget; 2018 Feb; 9(13):11209-11226. PubMed ID: 29541408
[TBL] [Abstract][Full Text] [Related]
7. Repolarization of Tumor-Infiltrating Myeloid Cells for Augmentation of CAR T Cell Therapies.
Luo W; Napoleon JV; Zhang F; Lee YG; Wang B; Putt KS; Low PS
Front Immunol; 2022; 13():816761. PubMed ID: 35250995
[TBL] [Abstract][Full Text] [Related]
8. ROS Scavenging Nanozyme Modulates Immunosuppression for Sensitized Cancer Immunotherapy.
Mo W; Liu S; Zhao X; Wei F; Li Y; Sheng X; Cao W; Ding M; Zhang W; Chen X; Meng L; Yao S; Diao W; Wei H; Guo H
Adv Healthc Mater; 2023 Aug; 12(21):e2300191. PubMed ID: 37031357
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer.
Zhang H; Liu Z; Wen H; Guo Y; Xu F; Zhu Q; Yuan W; Luo R; Lu C; Liu R; Gu J; Ge D
Cancer Immunol Immunother; 2022 Oct; 71(10):2511-2522. PubMed ID: 35278107
[TBL] [Abstract][Full Text] [Related]
10. Fatty Acid Metabolism in Myeloid-Derived Suppressor Cells and Tumor-Associated Macrophages: Key Factor in Cancer Immune Evasion.
Siddiqui S; Glauben R
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008414
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of immune surveillance in breast cancer by targeting hypoxic tumor endothelium: Can it be an immunological switch point?
Thomas JA; Gireesh Moly AG; Xavier H; Suboj P; Ladha A; Gupta G; Singh SK; Palit P; Babykutty S
Front Oncol; 2023; 13():1063051. PubMed ID: 37056346
[TBL] [Abstract][Full Text] [Related]
12. Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors.
Kes MMG; Van den Bossche J; Griffioen AW; Huijbers EJM
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188427. PubMed ID: 32961257
[TBL] [Abstract][Full Text] [Related]
13. All-trans-retinoic acid inhibits hepatocellular carcinoma progression by targeting myeloid-derived suppressor cells and inhibiting angiogenesis.
Li X; Luo X; Chen S; Chen J; Deng X; Zhong J; Wu H; Huang X; Wang C
Int Immunopharmacol; 2023 Aug; 121():110413. PubMed ID: 37301119
[TBL] [Abstract][Full Text] [Related]
14. FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion.
Zhao Z; Qin J; Qian Y; Huang C; Liu X; Wang N; Li L; Chao Y; Tan B; Zhang N; Qian M; Li D; Liu M; Du B
J Hematol Oncol; 2024 Feb; 17(1):9. PubMed ID: 38402237
[TBL] [Abstract][Full Text] [Related]
15. Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.
Olsson A; Nakhlé J; Sundstedt A; Plas P; Bauchet AL; Pierron V; Bruetschy L; Deronic A; Törngren M; Liberg D; Schmidlin F; Leanderson T
J Immunother Cancer; 2015; 3():53. PubMed ID: 26673090
[TBL] [Abstract][Full Text] [Related]
16. Generation of Human Immunosuppressive Myeloid Cell Populations in Human Interleukin-6 Transgenic NOG Mice.
Hanazawa A; Ito R; Katano I; Kawai K; Goto M; Suemizu H; Kawakami Y; Ito M; Takahashi T
Front Immunol; 2018; 9():152. PubMed ID: 29456539
[TBL] [Abstract][Full Text] [Related]
17. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
18. Blocked Autophagy is Involved in Layered Double Hydroxide-Induced Repolarization and Immune Activation in Tumor-Associated Macrophages.
Jing G; Yang L; Wang H; Niu J; Wang H; Gao Y; Li Y; Wei B; Qian Y; Wang S
Adv Healthc Mater; 2023 Dec; 12(30):e2301471. PubMed ID: 37549006
[TBL] [Abstract][Full Text] [Related]
19. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
Liu Z; Xie Y; Xiong Y; Liu S; Qiu C; Zhu Z; Mao H; Yu M; Wang X
Cancer Lett; 2020 Jan; 469():173-185. PubMed ID: 31629935
[TBL] [Abstract][Full Text] [Related]
20. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
[Next] [New Search]
